JP Morgan Maintains Overweight on Intersect ENT, Raises Price Target to $28

JP Morgan maintains Intersect ENT (NASDAQ:XENT) with a Overweight and raises the price target from $25 to $28.

Benzinga · 12/20/2019 14:37

JP Morgan maintains Intersect ENT (NASDAQ:XENT) with a Overweight and raises the price target from $25 to $28.